CIK 0000914475 · Large accelerated filer
NEUROCRINE BIOSCIENCES INC
Sign in to watch- Ticker
- NBIX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330525145
- Phone
- (858) 617-7600
- Business address
- 6027 EDGEWOOD BEND COURT, SAN DIEGO, CA, 92130
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,162,347
- in 4 filings, $3.2M under 10b5-1 plans
Net −$3,162,347. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-13 | ABERNETHY MATT Chief Financial Officer | Grant or award · Restricted Stock Unit | +7,735 | 7,735 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Option exercise | +1,961 | 55,639 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Shares withheld for taxes | −1,058 | $124.12 | $131K | 54,581 |
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Option exercise | +2,083 | 56,664 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Shares withheld for taxes | −1,124 | $124.12 | $140K | 55,540 |
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Grant or award | +16,613 | 72,153 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Shares withheld for taxes | −8,963 | $124.12 | $1.1M | 63,190 |
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Restricted Stock Unit | −1,961 | 3,924 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Option exercise · Restricted Stock Unit | −2,083 | 2,083 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Stock Option | +36,287 | 36,287 | ||
| 2026-02-13 | BENEVICH ERIC Chief Commercial Officer | Grant or award · Restricted Stock Unit | +6,365 | 6,365 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Option exercise | +2,241 | 146,254 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Shares withheld for taxes | −1,210 | $124.12 | $150K | 145,044 |
| 2026-02-13 | Gano Kyle Chief Executive Officer | Option exercise | +2,566 | 147,610 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Shares withheld for taxes | −1,385 | $124.12 | $172K | 146,225 |
| 2026-02-13 | Gano Kyle Chief Executive Officer | Grant or award | +9,968 | 156,193 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Shares withheld for taxes | −5,378 | $124.12 | $668K | 150,815 |
| 2026-02-13 | Gano Kyle Chief Executive Officer | Option exercise · Restricted Stock Unit | −2,241 | 4,484 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Option exercise · Restricted Stock Unit | −2,566 | 2,566 | ||
| 2026-02-13 | Gano Kyle Chief Executive Officer | Grant or award · Stock Option | +114,830 | 114,830 |
Page 11 of 49 · 963 trades